Product Description
APH01727 tablets are a highly active and highly selective glucagon-like peptide-1 receptor agonist (GLP‑1RA) independently developed by the company. The goal is to be an oral small molecule GLP-1R agonist administered once a day, and is intended for the treatment of patients with type 2 diabetes and overweight/obesity. (Sourced from: https://www.webull.com/news/10744771640438784)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yipinhong Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|